Last reviewed · How we verify
CP-690,550 Ointment 2
CP-690,550 is a Janus kinase (JAK) inhibitor.
CP-690,550 is a Janus kinase (JAK) inhibitor. Used for Rheumatoid arthritis.
At a glance
| Generic name | CP-690,550 Ointment 2 |
|---|---|
| Sponsor | Pfizer |
| Drug class | JAK inhibitor |
| Target | JAK |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
JAK inhibitors block the activity of JAK enzymes, which are involved in the signaling of various cytokines and growth factors. By inhibiting JAK enzymes, CP-690,550 reduces inflammation and immune responses.
Approved indications
- Rheumatoid arthritis
Common side effects
- Nausea
- Headache
- Diarrhea
- Fatigue
- Anemia
Key clinical trials
- CP-690-550 Ointment For Chronic Plaque Psoriasis (PHASE2)
- Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CP-690,550 Ointment 2 CI brief — competitive landscape report
- CP-690,550 Ointment 2 updates RSS · CI watch RSS
- Pfizer portfolio CI